Feng Zhang1,2, Feng Wang3, Weiguo Li4, Ning Wang1, Chunlei Han1, Shiying Fan1, Peng Li2, Lifeng Xu2, Jianguo Zhang5,6, Fangang Meng7,8,9,10. 1. Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China. 2. Department of neurosurgery, the First Hospital of Hebei Medical University, Shijiazhuang, 050031, Hebei, China. 3. Departments of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, 310000, Hangzhou, China. 4. Department of neurosurgery, QiLu Hospital of Shandong University, Jinan, 250012, China. 5. Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China. zjguo73@126.com. 6. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China. zjguo73@126.com. 7. Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China. fgmeng@ccmu.edu.cn. 8. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China. fgmeng@ccmu.edu.cn. 9. Beijing Key Laboratory of Neurostimulation, Beijing, 100070, China. fgmeng@ccmu.edu.cn. 10. Chinese Institute for Brain Research, Beijing, 102206, China. fgmeng@ccmu.edu.cn.
Abstract
BACKGROUND: To investigate the relationship between the position of bilateral STN-DBS location of active contacts and the clinical efficacy of STN-DBS on motor symptoms in Parkinson's disease (PD) patients. METHODS: Retrospectively analyze the clinical data of 57 patients with PD who underwent bilateral STN-DBS from March 2018 to December 2018. Unified Parkinson's Disease Rating Scale-Part III (UPDRS-III) score, levodopa equivalent day dose (LEDD), Parkinson's Disease Quality of Life Scale (PDQ-39) before operation and within 6 months after operation, determine the location of activated contacts and volume of tissue activated (VTA) in the Montreal Neurological Institute (MNI) space, and analyze their correlation with the improvement rate of motor symptoms (UPDRS-III score improvement rate). RESULTS: After 6 months of follow up, the UPDRS-III scores of 57 patients (Med-off) were improved by 55.4 ± 18.9% (P<0.001) compared with that before operation. The improvement rate of PDQ-39 scores [(47.4 ± 23.2)%, (P < 0.001)] and the reduction rate of LEDD [(40.1 ± 24.3)%, (P < 0.01)] at 6 months postoperation were positively correlated with the improvement rate of motor symptoms (Med-off)(PDQ-39:r = 0.461, P<0.001; LEDD: r = 0.354, P = 0.007), the improvement rate of UPDRS-III (Med-off) and the Z-axis coordinate of the active contact in the MNI space were positively correlated (left side: r = 0.349,P = 0.008;right side: r = 0.369,P = 0.005). In the MNI space, there was no correlation between the UPDRS-III scores improvement rate (Med-off) at 6 months after operation and bilateral VTA in the STN motor subregion, STN associative subregion and STN limbic subregion of the active electrode contacts of 57 patients (all P > 0.05). At 6 months after surgery, the difference between the Z-axis coordinate in the different improvement rate subgroups(<25, 25 to 50%, and>50%) in the MNI space was statistically significant (left side: P = 0.030; right side: P = 0.024). In the MNI space, there was no statistically significant difference between the groups in the VTA of the electrode active contacts (all P > 0.05). CONCLUSION: STN-DBS can improve the motor symptoms of PD patients and improve the quality of life. The closer the stimulation is to the STN dorsolateral sensorimotor area, the higher the DBS is to improve the motor symptoms of PD patients.
BACKGROUND: To investigate the relationship between the position of bilateral STN-DBS location of active contacts and the clinical efficacy of STN-DBS on motor symptoms in Parkinson's disease (PD) patients. METHODS: Retrospectively analyze the clinical data of 57 patients with PD who underwent bilateral STN-DBS from March 2018 to December 2018. Unified Parkinson's Disease Rating Scale-Part III (UPDRS-III) score, levodopa equivalent day dose (LEDD), Parkinson's Disease Quality of Life Scale (PDQ-39) before operation and within 6 months after operation, determine the location of activated contacts and volume of tissue activated (VTA) in the Montreal Neurological Institute (MNI) space, and analyze their correlation with the improvement rate of motor symptoms (UPDRS-III score improvement rate). RESULTS: After 6 months of follow up, the UPDRS-III scores of 57 patients (Med-off) were improved by 55.4 ± 18.9% (P<0.001) compared with that before operation. The improvement rate of PDQ-39 scores [(47.4 ± 23.2)%, (P < 0.001)] and the reduction rate of LEDD [(40.1 ± 24.3)%, (P < 0.01)] at 6 months postoperation were positively correlated with the improvement rate of motor symptoms (Med-off)(PDQ-39:r = 0.461, P<0.001; LEDD: r = 0.354, P = 0.007), the improvement rate of UPDRS-III (Med-off) and the Z-axis coordinate of the active contact in the MNI space were positively correlated (left side: r = 0.349,P = 0.008;right side: r = 0.369,P = 0.005). In the MNI space, there was no correlation between the UPDRS-III scores improvement rate (Med-off) at 6 months after operation and bilateral VTA in the STN motor subregion, STN associative subregion and STN limbic subregion of the active electrode contacts of 57 patients (all P > 0.05). At 6 months after surgery, the difference between the Z-axis coordinate in the different improvement rate subgroups(<25, 25 to 50%, and>50%) in the MNI space was statistically significant (left side: P = 0.030; right side: P = 0.024). In the MNI space, there was no statistically significant difference between the groups in the VTA of the electrode active contacts (all P > 0.05). CONCLUSION: STN-DBS can improve the motor symptoms of PDpatients and improve the quality of life. The closer the stimulation is to the STN dorsolateral sensorimotor area, the higher the DBS is to improve the motor symptoms of PDpatients.
Entities:
Keywords:
Active contacts; Deep brain stimulation; Motor symptom; Parkinson’s disease; Subthalamic nucleus; Volume of tissue activated
Authors: Chen Yao; Andreas Horn; Ningfei Li; Yang Lu; Zonghui Fu; Ning Wang; Tipu Z Aziz; Lin Wang; Shizhong Zhang Journal: Parkinsonism Relat Disord Date: 2018-07-10 Impact factor: 4.891
Authors: S J G Lewis; T Foltynie; A D Blackwell; T W Robbins; A M Owen; R A Barker Journal: J Neurol Neurosurg Psychiatry Date: 2005-03 Impact factor: 10.154
Authors: Ahmed Rabie; Leo Verhagen Metman; Mazen Fakhry; Ayman Youssef Ezeldin Eassa; Wael Fouad; Ahmed Shakal; Konstantin V Slavin Journal: Brain Sci Date: 2016-12-13
Authors: Sunderland Baker; Anand Tekriwal; Gidon Felsen; Elijah Christensen; Lisa Hirt; Steven G Ojemann; Daniel R Kramer; Drew S Kern; John A Thompson Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752
Authors: Jerrold L Vitek; Rémi Patriat; Lisa Ingham; Martin M Reich; Jens Volkmann; Noam Harel Journal: Front Neurosci Date: 2022-10-04 Impact factor: 5.152